ANTX Projected Dividend Yield

AN2 Therapeutics Inc ( NASDAQ : ANTX )

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis.

20 YEAR PERFORMANCE RESULTS